Debate over the heart attack risk associated with the GlaxoSmithKline diabetes drug Avandia took center stage Monday at the annual meeting of the American Diabetes Association.
Cleveland Clinic chief cardiologist Dr. Steve Nissen defended his "meta-analysis," published in May in The New England Journal of Medicine, concluding that use of Avandia appears to significantly increase the risk of heart attacks, a finding Glaxo refutes.
"When you see this kind of consistency in data, it makes you believe that something real is going on," said Dr. Nissen.
More and More
Cleveland Clinic chief cardiologist Dr. Steve Nissen defended his "meta-analysis," published in May in The New England Journal of Medicine, concluding that use of Avandia appears to significantly increase the risk of heart attacks, a finding Glaxo refutes.
"When you see this kind of consistency in data, it makes you believe that something real is going on," said Dr. Nissen.
More and More
No comments:
Post a Comment